Peter Lurie, a former FDA official who now leads the Center for Science in the Public Interest
Microbes little helpers and suppliers for therapeutic asthma approaches
While steady progress has been made in the understanding of NAFL/NASH pathophysiology and identification of therapeutic targets, relatively slow progress was achieved in the treatment of all aspects of NAFL/NASH even after years of intense research, 5,13,45 although several approved drugs for treating metabolic-related disorders and diseases showed promising outcomes in patients with NAFL/NASH, including Orlistat 46 used for the treatment of obesity (Fig
Pourebrahim R , Khanna P, Yang D, Muftuoglu M, Ostermann LB, Khazaei S, Zhao R, Asare A, Hajek RA, Lee S, Corvingo S, Gagea M, Sood A, Li R, Takahashi K, Andreeff M